even without having one approved FDA product hahah so wild....ATRS has how many and you as a investor haven't even figure out why the disparancy. Join me and whogo over at ACAD
ACAD will prob. be stock of the year, since its drug has so much impact on people who suffer from the disease. PSDV, with its impact on eye disease, is also a contender, as well as RAD, a huge turn around story.